Oestrogens are important mitogens for human breast cancer cells in vitro and in vivo, acting directly or by enhancing secretion of peptide growth factors (Lippman & Dickson, 1990) . Oestrogens are synthesised from androgens by an enzyme complex made up of the cytochrome P450 aromatase and the flavoprotein NADPH cytochrome P450 reductase (Lephart & Simpson, 1991) . Aromatase activity is expressed in the endoplasmic reticulum of placenta (Fournet-Dulgerov et al., 1987) and also in ovarian granulosa cells (McNatty et al., 1976) and adipose tissue (Simpson et al., 1989) , the main sites of oestrogen synthesis in pre-and post-menopausal women respectively.
Aromatase activity is detectable in homogenates of 60-70% of primary and metastatic breast cancers. Enzyme assays reveal activity in the range 5 -80 pmol g-' h-', with 0.02-0.9% conversion of androstenedione to oestrone (El) or testosterone to oestradiol (E2; Varela & Dao, 1978; Miller et al., 1982 Miller et al., , 1990 Bezwoda et al., 1987a; Lipton et al., 1987; Silva et al., 1989) . Opinions vary as to whether this is sufficient to produce mitogenic concentrations of E2 (Bradlow, 1982 : Miller et al., 1990 . Given circulating androgen levels in the 10-9 M range, it seems likely that the observed conversion rates for androstenedione and testosterone could generate El and E2 levels approaching 10-" M, which are mitogenic to MCF-7 breast cancer cells in vitro (Maclndoe, 1979; Kitiwaki et al., 1992) .
Although clinical studies have produced consistent estimates of the amount of aromatase expressed in breast cancers, there is little agreement on the biological importance of intratumoral aromatase. It is not clear whether aromatase expression correlates with known prognostic indicators such as tumour size, grade and oestrogen receptor status (Miller et al., 1982 (Miller et al., , 1990 Bezwoda et al., 1987a, b; Lipton et al., 1988; Silva et al., 1989; Bolufer et al., 1992; Esteban et al., 1992) . In order to assess the phenotypic effects of aromatase expression on breast cancer cells in vitro, we transfected a hormoneresponsive breast cancer cell line with aromatase.
Materials and methods
Aromatase expression plasmid Human placental poly(A)+ RNA (Cambridge Bioscience, UK) (Gibco-BRL) and oligo dT as previously described (Ashworth, 1993) . Aromatase cDNA was amplified by polymerase chain reaction (PCR) using forward and reverse oligonucleotide primers CTAAGCTTAAGGAACACAAGATGGTTTTGG and AAGCGGCCGCTAGTGTTCCAGACACCTGTC, incorporating HindIII and NotI restriction sites flanking the initiation (ATG) and termination (TAG) codons respectively (Corbin et al., 1988 (Seed & Aruffo, 1987) (Chen, 1977) . MCF-7 cells were transfected with p3681 by electroporation in HEPES-buffered saline (20 mM HEPES pH 7.05, 137 mM sodium chloride, 5 mm potassium chloride, 0.7 mM disodium hydrogen phosphate, 6 mM dextrose) as described by Chu et al. (1987) .
After 48 h 600 yg ml-' G418 (Gibco) was added to the medium to select for cells carrying the plasmid. After a further 16 days G418-resistant colonies were picked for individual culture, and were maintained in CM with G418 at 600 tLg ml-' Before experiments in steroid-depleted conditions, MCF-7 cells were cultured for 10 days in phenol red-free RPMI and 5% charcoal-stripped serum (steroid-depleted medium, SDM), plus 600 gg ml-' G418 for resistant clones Aromatase activity was measured in intact cells by tritiated water release and product isolation assay (Lephart & Simpson, 1991 [lP-3H] androstenedione. Progesterone (1 ,M; Sigma) was added to inhibit 5ax-reductase activity (Zhou et al., 1990) . CGS 16949A and 4-hydroxyandrostenedione (gifts from Ciba-Geigy Pharmaceuticals) were dissolved in methanol and added to the medium to achieve the correct final concentration. At timed intervals 250 1sl of supernatant was removed, added to 1.5 ml of ethyl acetate, shaken and incubated at room temperature for 30 min. The samples were centrifuged at 1,500 g for 15 min. The supernatant was discarded and 200 pl of the aqueous phase was added to 250 gsl of dextran-coated charcoal (5% charcoal, 0.5% dextran T70) in 0.25% Tween 80. The tubes were shaken and incubated on ice for 30 min. After centrifugation (4°C, 3,000 r.p.m., 30 min), 200yl of the supernatant was counted on a Packard 300C liquid scintillation counter. Cell monolayers were washed with 50 mm sodium phosphate buffer pH 7.4, dissolved in 0.5 M sodium hydroxide, and the protein content was determined by the method of Bradford (1976) . The WT and transfected clones were compared in a prolonged (24 h) assay which used the method as above, with 16 nM [1p-3H]androstenedione. Tritiated water release that was inhibited by 500 nM CGS 16949A was considered to represent specific aromatase activity.
Tissue culture medium was prepared for TLC by extraction with diethyl ether. The aqueous layer was frozen on dry ice/acetone permitting separation of the extracted steroids in ether. The ether was evaporated at 40°C and samples were reconstituted in dichloromethane (DCM). Standards (testosterone, androstenedione, El, E2) and triplicate samples were applied to TLC plates (Merck) and were run for 90 min in DCM-ethyl acetate-methanol (80:20:1). A Berthold LB283 TLC linear analyser was used to locate and quantify radioactive peaks. The products were localised by reference to the mobility of the standards, rather than by further chromatography and crystallisation. TLC analysis was performed on triplicate samples from each of two separate experiments, with very similar results. The results show values obtained in a single experiment.
Oestrogen receptor assay Oestrogen receptor (ER) concentrations were measured in subconfluent cultures growing in CM. Cell homogenates were prepared using a dismembrator (Braun) and the resultant powder was suspended in assay buffer. Crude cytosol and nuclear fractions were prepared by centrifugation (3,000g) and the cytosols were used for enzyme immunoassay (Abbott).
Results

Molecular characterisation of transfected MCF-7 clones
Transient expression of p3610 in COS cells confirmed that the cDNA encoded active aromatase enzyme (data not shown). The efficiency of transfection of MCF-7 cells with p3681 was 1.4%, representing 500 G418-reistant colonies per pg of DNA. Clones Arom. 1 and Arom. 2 were selected for further study, and incorporation of p3681 was assessed by Southern, Northern and Western analysis (Figure 1 ). The Southern blot (Figure la) showed bands of 4.8, 5.0, 5.2 and 11 kb, representing the EcoRI-digested endogenous aromatase gene, in WT, Arom. 1 and Arom. 2 genomic DNA. An additional 2 kb band representing the transfected plasmid was detected in Arom. 1 and less intensely in Arom. 2. In neither case was the intensity similar to that of the endogenous gene, indicating that the plasmid was present at lower copy number. Northern analysis revealed a 1.5 kb aromatase transcript in Arom. 1 cells, and a fainter band of 3.5 kb, probably representing an unspliced nuclear precursor (Figure lb) . Aromatase transcripts were undetectable in WT and Arom. 2 cells under these conditions. Western blot analysis ( Figure Ic ) using polyclonal antibody R-8-2 (Kitiwaki et al., 1989) showed a single band of approximately 50 kDa in Arom. 1 but not in Arom. 2 or WT cell lysates. Thus, aromatase cDNA was incorporated into MCF-7 clones Arom. 1 and 2, but only Arom. 1 produced significant aromatase mRNA and protein.
Aromatase activity Aromatase assay was used to ascertain whether the presence of aromatase mRNA and protein in MCF-7 cells was leading to production of functional enzyme. Assays showed significantly increased aromatase activity in Arom. 1 cells. Tritiated water release was linear with time up to 2 h. The Km was 70 nm and the Vm. was 7.1 pmol 3H20 released per mg of protein per hour, similar to the values of 55.6 nM and 10 pmol mg' h-' reported by Zhou et al. (1990) . Stably expressed aromatase activity was inhibited in Arom. 1 cells by both CGS 16949A and 4-hydroxyandrostenedione, with ICm values of 7.4 and 70 nM respectively. At 2 h, WT and Arom. 2 cells had no detectable aromatase activity. After 24 h incubation, aromatase activity was detected in WT (12 fmol mg-' protein 24 h-') and Arom. 2 (3 fmol mg'I 24 h-'). This was approximately 1,000 times lower than that present in Arom. 1 (6120 fmol mg-' 24 h-').
Morphology, ER expression, cell culture The light microscopic appearances of Arom. 1 and Arom. 2 were not significantly different from WT (not shown). ER expression was detected in WT, Arom. 1 and Arom. 2 cell lines at 130 fmol per mg of protein.
When cultured in complete medium (CM) there was no significant difference in the growth rates of WT, Arom. 1 or Arom. 2 cells (data not shown). However, a difference in growth rate was observed in steroid-depleted medium (SDM): after 6 days the number of Arom. 1 cells was significantly higher than the number of WT In evaluating the growth characteristics of Arom. 1, we used the Arom. 2 clone as control, since this cell line, like Arom. 1, had undergone transfection and G418 selection, but did not express aromatase activity at levels greater than WT. Figure 3 shows the effect of androstenedione, testosterone or Figure 4 . After 24 h culture in medium containing 1.6 nM [7-3H] testosterone, product isolation analysis revealed that 46% of the substrate had been converted to E2. Dihydrotestosterone, the product of 5a-reductase activity, has very similar mobility to E2 on TLC, and in theory could contaminate the 'E2' peaks generated by Arom. 1. However, WT Al A2 b 10-4-3-2-significant contamination is thought to be unlikely because little or no 'E,' was generated by Arom. 2 cells, which should have similar 5o-reductase activity (see below, Figure 4c ). By day 6 Arom. 1 cells had converted 100% of the substrate to oestrogen (16% E,, 84% E,; Figure 4a ). This was associated with significant enhancement of cell growth on day 6 (4.6 ± 0.2 x lO5 cells per well compared with 1.6 ± 0.1 x l05 in control cultures, P<0.01, Figure 4c ). In both day 1 and day 6 samples, aromatisation of 1.6 nM [7-3H]testosterone was completely inhibited by 500 nM CGS 16949A. Cell numbers were significantly lower than in the absence of CGS 16949A (2.6 ± 0.7 v.s 4.6 ± 0.2 x 105, P<0.01), and not significantly different from the cell number in control cultures. The higher [7-'H] testosterone concentration of 16 nM was almost completely converted to E2 (82%) by day 1. On day 6, 63.5% of tritiated product was identified as E2, and 22.5% was an unidentified peak. There was significant growth enhancement (2.6 ± 0.4 x 105 cells per well, P<0.05), although the effect here was less than in cultures supplemented with 1.6 nM [7-3H] testosterone, suggesting production of a higher concentration of E, than the 10 to 10 9 M range previously found to be optimal. As at the lower substrate concentration, CGS 16949A completely suppressed conversion of testosterone to E, during the first 24 h. By day 6 there had been negligible conversion to E, (8%), 62.5% steroid remained as testosterone and 21.50% was in an unidentified peak. This suppression of aromatase activity was associated with growth delay (1.1 ± 0.20 x 10t vs 2.6 ± 0.4 x 105 in the absence of CGS 16949A, P<0.01), with cell nurhbers falling to the level observed in control cultures.
Results of the parallel experiment on Arom. 2 are shown in Figure 4b and d. No significant aromatase activity was detected in these cells on day 1, or on day 6 at the lower [7-3H]testosterone concentration, 1.6 nM. After 6 days in the presence of 16 nM substrate, there was 13% conversion to E,. This was not suppressed by CGS 16949A. Arom. 2 cell numbers showed no significant differences from control in the presence or absence of [7-3H] testosterone or aromatase inhibitor.
Discussion
The aim of this study was to assess the biological significance of intratumoral aromatase expression, particularly in areas in which studies of clinical material have yielded conflicting data. To this end we first sought to confirm that transfected MCF-7 cells expressed aromatase, comparing the level of enzyme activity with that detectable in clinical samples of breast cancer.
Molecular analysis confirmed incorporation of aromatase cDNA into MCF-7 clones Arom. 1 and Arom. 2. In both clones the transfected plasmid was present at lower copy number than the endogenous aromatase gene. A similar finding, compatible with amplification of the endogenous gene, was made by Zhou et al. (1990) when expressing aromatase in mammalian cells for screening of new inhibitors. We detected high levels of expressed aromatase by Northern and Western analysis in clone Arom. 1 but not WT or Arom. 2. As we have previously reported (Ryde et a!., 1992) , WT cells have detectable aromatase activity, which we and others (Zhou ct al., 1990; Pizzini et al., 1992) found too low for full kinetic analysis. Despite incorporation of the expression construct, Arom. 2 cells did not have aromatase activity above WT levels. The reason for this is unclear.
Enzyme assay of Arom. 1 revealed a Km of 7.1 pmol mg-' h-'. The results of 24 h assay showed these cells to express approximately 1,000 times more aromatase activity than WT or Arom. 2 cells. We observed 100% conversion of physiological levels of testosterone (10-9 to 10-8 M) to oestrogens in Arom. 1 cells (Figure 4 ). This represents 100-1,000 times the level of aromatase activity in clinical tumour specimens (Varela & Dao. 1978 : Miller et al., 1982 , 1990 ; Lipton Silva et al., 1989) . Enzyme activity in clinical tumour homogenates reflects aromatase expressed by the tumour cells, and at lower levels, by breast adipose cells (Perel et al., 1982) . Extracellular matrix makes no contribution; indeed aromatase activity is higher in highly cellular tumours than in those of moderate/low cellularity (Miller et al., 1990 (Silva et al., 1989 ), Lipton et al. (1988 found no correlation between intratumoral aromatase expression and degree of differentiation. In support of this conclusion we found that overexpression of aromatase had no effect on the morphology of cultured cells. Similarly we found no difference in levels of ER expression between Arom. 1 and WT cells. Some clinical studies have found a positive correlation between intratumoral aromatase expression and ER positivity (Miller et al., 1982 (Miller et al., , 1990 Bolufer et al., 1992) . Others suggest that aromatasepositive tumours are more often ER negative (Abul-Haji et al., 1979; Esteban et al., 1992) Most breast cancers are thought to be hormone dependent early in their natural history (Lippman & Dickson, 1990) , and so aromatase activity may affect the growth of the tumour. Local oestrogen production may enhance growth of the aromatase-positive cells and, in a paracrine fashion, adjacent aromatase-negative cells. Several studies have attempted to correlate aromatase activity with clinical prognostic factors and response to treatment (Bezwoda et al., 1987a,b; Silva et al., 1989; Miller et al., 1990; Bolufer et al., 1992) . In our in vitro model we found no growth difference in complete medium, as serum provides sufficient oestrogen for optimal growth. However in SDM Arom. 1 cells grew faster than WT or Arom. 2 (Figure 2) . We have no definite explanation for this observation, but it is consistent with a response to residual androgen remaining in SDM after charcoal stripping of serum. There was more marked growth enhancement on addition of androstenedione or testosterone. We did not observe a response to androgens in Arom. 2 or WT cells; neither cell line grew in the absence of exogenous oestrogen. However, there is evidence for heterogeneity of aromatase expression in WT MCF-7 cells, sufficient to permit some sublines to grow in androgen-supplemented SDM (Darbre & Daly, 1989; Kitiwaki et al., 1992 (Figure 3) . Alternatively, it could be due to suppression of the mitogenic response to any residual androgen remaining in SDM, but we have no direct evidence for this. CGS 16949A also caused complete suppression of the mitogenic effect of 10-11 M androstenedione or testosterone. Experiments with tritiated substrates enable us to correlate directly aromatase activity and growth enhancement, and to assess the inhibition of enzyme activity and growth by CGS 16949A. Here we used androgen concentrations of 1.6-16 nM, equivalent to circulating levels in postmenopausal women (Judd et al., 1974) . We did not purify 'oestrogens' separated by TLC, but significant contamination of these peaks with other products seemed unlikely for several reasons. The negligible loss of testosterone to other peaks (in particular those associated with El or E2) in Arom. 2 cells indicates little underlying metabolism of this precursor to oestrogens or other products coincident on TLC. In Arom. 1 cells there was good correlation between conversion of testosterone to E2, which was generally complete after 24 h, and growth enhancement observed on day 6. CGS 16949A, a highly selective aromatase inhibitor, caused virtual obliteration of 'oestrogen' peaks generated by Arom. 1 cells. This was accompanied by complete suppression of androgen-stimulated growth, again supporting the view that oestrogens were the main products of testosterone metabolism by the Arom. 1 clone.
In summary.we have developed a clone of MCF-7 cells which stably overexpresses aromatase at 1,000 times the level in WT cells. This had no detectable effect on morphology, ER expression or response to E2. However, there was significant growth enhancement in steroid-depleted conditions, and this growth advantage over WT cells was further enhanced by exogenous androgens. These changes were fully reversible by aromatase inhibitors. We plan to evaluate the growth characteristics of Arom. 1 cells in vivo. The ability to manipulate aromatase expression by breast cancer xenografts should help to clarify the significance of intratumoral aromatase detectable in clinical breast tumours.
